COLLECTINS IN VAGINAL MUCOSAL HOST DEFENSE

阴道粘膜宿主防御中的集合素

基本信息

  • 批准号:
    6380027
  • 负责人:
  • 金额:
    $ 23.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-09-01 至 2004-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (adapted from applicant's abstract): The vaginal mucosa (VM) is one of the critical interfaces between host and pathogens. Normally, it can tolerate and contain a broad range of microbes and cope with foreign proteins including those present in the ejaculate. Hence, VM is likely to be equipped with an arsenal of defenses similar to that of the other such mucosal interfaces, e.g., lung and gut. This proposal focuses on vaginitis, a condition resulting from a breakdown of defenses against organisms that remain largely localized yet can have major consequences for the host and her reproductive capacity. Vaginitis is responsible for up to 15% of patient visits to women's health practices. The sequelae of VM have great effects on public health, and are implicated in disorders ranging from preterm labor and associated morbidity and mortality of the offspring, to increased susceptibility to sexually transmitted disease and progression of cervical neoplasia. Yet, knowledge of vaginal host defenses has lagged behind that of other mucosal surfaces. Here we propose to follow up on evidence obtained by us that SP-A is expressed in VM and is present in VF by testing the hypotheses that: (1) SP-A in VF, as in lung, contributes to host defenses by modulating cytokine production and facilitating phagocytosis; (2) SP-A expression in VM and function in VF, like other mediators of vaginal immunity, vary with menstrual cycle (i.e., is hormonally regulated); and (3) aberrant SP-A homeostasis contributes to recurrent vulvovaginal candidiasis (RVVC), a prevalent, intractable condition of women of reproductive age that is characterized by episodes of exacerbations of inflammation of the VM due to colonization of the vagina with C. albicans. Parameters relevant to SP-A function will be compared: (1) in healthy women at three stages of the menstrual cycle; (2) in healthy women and RVVC patients; and (3) in RVVC patients during remissions and exacerbations of the disease. In VM, SP-A will be localized by immunocytochemistry and gene-specific message levels will be estimated by reverse transcriptase/polymerase chain reaction (RT/PCR). In VF, SP-A levels will be measured by enzyme-linked immunoabsorbent assay (ELISA), SP-A oligomeric size established by gel filtration and ability of SP-A to stimulate production of proximal cytokines and to facilitate phagocytosis. This will be accomplished using THP-1 macrophages adapted to grow as surrogates for vaginal macrophages in a medium that simulates VF fluid with respect to certain determinants of SP-A function, such as pH, electrolyte and cation concentrations. Immunodepletion will be used to determine the contribution made by SP-A to stimulation of cytokine production by TPH-1 cells.
描述(改编自申请人的摘要):阴道粘膜(VM)是 宿主和病原体之间的关键界面之一。 正常情况下是可以的 耐受并包含多种微生物并应对外来蛋白质 包括精液中存在的物质。 因此,VM很可能配备 具有与其他粘膜相似的防御手段 界面,例如肺和肠。 该提案的重点是阴道炎, 由于对残留有机体的防御崩溃而导致的状况 很大程度上是本地化的,但可能会对主人和她产生重大影响 生殖能力。 高达 15% 的患者患有阴道炎 参观妇女的健康实践。 VM后遗症影响很大 公共卫生,并与早产和早产等疾病有关 后代的相关发病率和死亡率,以增加 性传播疾病的易感性和宫颈癌的进展 瘤形成。 然而,对阴道宿主防御的了解却落后于人类的了解。 其他粘膜表面。 在此,我们建议对所获得的证据进行跟进 通过检验假设,我们知道 SP-A 在 VM 中表达并且在 VF 中存在 (1) VF 中的 SP-A 与肺中一样,通过调节来促进宿主防御 细胞因子的产生并促进吞噬作用; (2) SP-A在VM中的表达 与阴道免疫的其他介质一样,VF 中的功能和功能也随 月经周期(即受激素调节); (3) 异常 SP-A 体内平衡导致复发性外阴阴道念珠菌病 (RVVC) 育龄妇女普遍存在的棘手病症是 其特点是 VM 炎症加剧,原因是 白色念珠菌在阴道定植。 SP-A相关参数 功能比较: (1) 健康女性的三个阶段 月经周期; (2)健康女性和RVVC患者;和 (3) 在 RVVC 中 疾病缓解和恶化期间的患者。 在VM中,SP-A将 通过免疫细胞化学和基因特异性信息水平进行定位 通过逆转录酶/聚合酶链反应(RT/PCR)估计。 在VF中, SP-A水平将通过酶联免疫吸附测定(ELISA)测量, 通过凝胶过滤确定 SP-A 寡聚体大小以及 SP-A 的能力 刺激近端细胞因子的产生并促进吞噬作用。 这将使用适应生长的 THP-1 巨噬细胞来完成 在模拟 VF 液体的培养基中替代阴道巨噬细胞 SP-A 功能的某些决定因素,例如 pH、电解质和 阳离子浓度。 免疫耗竭将用于确定 SP-A 对刺激 TPH-1 产生细胞因子的贡献 细胞。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

COLIN MACNEILL其他文献

COLIN MACNEILL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('COLIN MACNEILL', 18)}}的其他基金

SURFACTANT PROTEIN-LIPID BALANCE: MODULATING LOWER GENITAL TRACT INFLAMMATION
表面活性剂蛋白质-脂质平衡:调节下生殖道炎症
  • 批准号:
    7951266
  • 财政年份:
    2009
  • 资助金额:
    $ 23.49万
  • 项目类别:
COLLECTIN -MEDIATED INNATE IMMUNITY IN VULVODYNIA
集合素介导的外阴痛的先天免疫
  • 批准号:
    7378451
  • 财政年份:
    2006
  • 资助金额:
    $ 23.49万
  • 项目类别:
IMMUNE MOD BY VAGINAL SURFACTANT PROTEIN: ROLE IN NORMAL PREGNANCY & PRETERM LAB
阴道表面活性蛋白的免疫调节:在正常妊娠中的作用
  • 批准号:
    7203520
  • 财政年份:
    2005
  • 资助金额:
    $ 23.49万
  • 项目类别:
Collectin-mediated innate immunity in vulvodynia
外阴痛中集合素介导的先天免疫
  • 批准号:
    7044381
  • 财政年份:
    2003
  • 资助金额:
    $ 23.49万
  • 项目类别:
COLLECTINS IN VAGINAL MUCOSAL HOST DEFENSE
阴道粘膜宿主防御中的集合素
  • 批准号:
    6198040
  • 财政年份:
    2000
  • 资助金额:
    $ 23.49万
  • 项目类别:
MOLECULAR BASIS FOR GATA-5 GENE EXPRESSION
GATA-5 基因表达的分子基础
  • 批准号:
    2211677
  • 财政年份:
    1996
  • 资助金额:
    $ 23.49万
  • 项目类别:
MOLECULAR BASIS FOR GATA-5 GENE EXPRESSION
GATA-5 基因表达的分子基础
  • 批准号:
    2445031
  • 财政年份:
    1996
  • 资助金额:
    $ 23.49万
  • 项目类别:
NEGATIVE REGULATION OF A VITELLOGENIN PROMOTER
卵黄蛋白原启动子的负调控
  • 批准号:
    3085974
  • 财政年份:
    1992
  • 资助金额:
    $ 23.49万
  • 项目类别:
NEGATIVE REGULATION OF A VITELLOGENIN PROMOTER
卵黄蛋白原启动子的负调控
  • 批准号:
    3085975
  • 财政年份:
    1992
  • 资助金额:
    $ 23.49万
  • 项目类别:
NEGATIVE REGULATION OF A VITELLOGENIN PROMOTER
卵黄蛋白原启动子的负调控
  • 批准号:
    2084294
  • 财政年份:
    1992
  • 资助金额:
    $ 23.49万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.49万
  • 项目类别:
    Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 23.49万
  • 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 23.49万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 23.49万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 23.49万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 23.49万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 23.49万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 23.49万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 23.49万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 23.49万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了